Company Filing History:
9 out of 106 
2 out of 14 
2 out of 923 
Years Active: 2017-2025
Title: John Buell: Innovator in Modulation Compounds
Introduction
John Buell is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of compounds and methods for CD73 modulation. With a total of 14 patents to his name, Buell's work has the potential to impact various therapeutic areas.
Latest Patents
Buell's latest patents include innovative compounds aimed at modulating CD73. One of his notable inventions is titled "Compounds and methods for CD73 modulation and indications therefor." This patent discloses compounds of Formula I that are designed to enhance therapeutic efficacy. Another significant patent is "Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof." This invention provides bifunctional compounds that act as HPK1 degraders via the ubiquitin proteasome pathway, offering methods for treating diseases influenced by HPK1.
Career Highlights
Throughout his career, John Buell has worked with leading companies in the biotechnology sector. He has been associated with Plexxikon Inc. and Nurix Therapeutics, Inc., where he has contributed to groundbreaking research and development efforts. His expertise in modulation compounds has positioned him as a key player in the industry.
Collaborations
Buell has collaborated with several notable professionals in his field, including Wayne Spevak and Jiazhong Zhang. These collaborations have further enriched his research and innovation endeavors.
Conclusion
John Buell's contributions to the field of biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic applications.